- Conard SE, Bays HE, Leiter LA, et al.
- Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
- Am J Cardiol. 2008;102(11):1489–1494.
- Download the Journal Reprint in EXE format
[EXE: 3.61 MB, 6 pages]- Leiter LA, Bays H, Conard S, et al.
- Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
- Am J Cardiol. 2008;102(11):1495–1501.
- Download the Journal Reprint in EXE format
- [EXE: 3.70 MB, 7 pages]
- Stein E, Stender S, Mata P, et al; for Ezetimibe Study Group.
- Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
- Am Heart J. 2004;148(3):447–455.
- Download the Journal Reprint in PDF Format
[PDF: 210 KB, 9 pages]- Ballantyne CM, Houri J, Notarbartolo A, et al; for Ezetimibe Study Group.
- Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
- Circulation. 2003;107(19):2409–2415.
- Download the Journal Reprint in EXE format
- [EXE: 3.33 MB, 7 pages]
- Gagné C, Bays HE, Weiss SR, et al; for Ezetimibe Study Group.
- Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
- Am J Cardiol. 2002;90(10):1084–1091.
- Download the Journal Reprint in PDF Format
- [PDF: 285 KB, 8 pages]
- Farnier M, Freeman MW, Macdonell G, et al; for Ezetimibe Study Group.
- Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
- Eur Heart J. 2005;26(9):897–905.
- McKenney JM, Farnier M, Lo K-W, et al.
- Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
- J Am Coll Cardiol. 2006;47(8):1584–1587.
- Download these 2 Journal Reprints in PDF Format
- [PDF: 221 KB, 13 pages]
- Turley SD, Dietschy JM.
- The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level.
- Prev Cardiol. 2003;6(1):29–33, 64.
- Download the Journal Reprint in PDF Format
- [PDF: 2,275 KB, 7 pages]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
- JAMA. 2001;285(19):2486–2497.
- Download the Journal Reprint in PDF Format
- [PDF: 248 KB, 11 pages]
[EXE: 3.61 MB, 6 pages]
[PDF: 210 KB, 9 pages]
Important Information About ZETIA
The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough.
Contraindications: hypersensitivity to any component of this medication.
Statin contraindications apply when used with a statin: active liver disease; unexplained persistent elevations in hepatic transaminase levels. Statins are contraindicated in pregnant and nursing women. Refer to the statin label for details.
When using ZETIA with a statin, also follow the label recommendations for that specific statin.
Selected Cautionary Information: When ZETIA was coadministered with a statin, consecutive elevations in hepatic transaminase levels (>3 x ULN) were slightly higher (1.3%) than those of statins alone (0.4%). Liver function tests should be performed when ZETIA is added to statin therapy and according to statin recommendations. Should an increase in ALT or AST >3 x ULN persist, consider withdrawal of ZETIA and/or the statin.
Patients should be advised to promptly report muscle pain, tenderness, or weakness. Risk for skeletal muscle toxicity increases with higher statin doses, advanced age (>65), hypothyroidism, renal impairment, and depending on the statin used, concomitant use of other drugs. Discontinue drug if myopathy is diagnosed or suspected.
ZETIA is not recommended in patients with moderate to severe hepatic impairment.
The coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.
Exercise caution when using ZETIA and cyclosporine concomitantly because exposure to both drugs is increased. Cyclosporine concentrations should be monitored in these patients.
ZETIA should be used in pregnant or nursing women only if the benefit outweighs the risk.
In clinical trials, regardless of causality assessment, the most frequent side effects for ZETIA coadministered with a statin vs statin alone included nasopharyngitis (3.7% vs 3.3%), myalgia (3.2% vs 2.7%), upper respiratory tract infection (2.9% vs 2.8%), arthralgia (2.6% vs 2.4%), and diarrhea (2.5% vs 2.2%); for ZETIA administered alone vs placebo: upper respiratory tract infection (4.3% vs 2.5%), diarrhea (4.1% vs 3.7%), arthralgia (3.0% vs 2.2%), sinusitis (2.8% vs 2.2%), and pain in extremity (2.7% vs 2.5%).
Before prescribing ZETIA, please read the Prescribing Information.
For non-US health care professionals, click here.
